ALIUPATINIB

COMPOSITION
Upadacitinib………………………………15mg
INDICATION

  • Adults who have had an inadequate response or intolerance to one or more TNF blockers having the following conditions:
    • Moderate to severe active rheumatoid arthritis.
    • Active psoriatic arthritis.
    • Moderate to severe ulcerative colitis.
    • Moderate to severe Crohn’s disease.
    • Active ankylosing spondylitis.
    • Active non-radiographic axial spondylarthritis.
  • Adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

PACKAGING: 15 mg/Tablet;28 Tablets/box.
Reg No: 11 L 1260/24
Download ALIUPATINIB Drug Registration Certificate

Brand name: ALIUPATINIB


Composition:
Each tablet contains:
Upadacitinib………………………………15mg


Indications:

  • Adults who have had an inadequate response or intolerance to one or more TNF blockers having the following conditions:
    • Moderate to severe active rheumatoid arthritis.
    • Active psoriatic arthritis.
    • Moderate to severe ulcerative colitis.
    • Moderate to severe Crohn’s disease.
    • Active ankylosing spondylitis.
    • Active non-radiographic axial spondylarthritis.
  • Adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

Dosage: Use under the guidance of a physician.


Contraindications:
Allergies to the active ingredient or any excipients of this product, active tuberculosis, active severe bacterial infection, severe liver function impairment, pregnant women: contraception should be used during medication.


Warnings:
• Severe infection: Avoid use in patients with active severe infection, including local infection.
• Gastrointestinal (GI) perforation.
• It is recommended to monitor changes in lymphocytes, neutrophils, hemoglobin, liver enzymes and lipids.
• Lactating women should stop breastfeeding during medication.
• Vaccination: Avoid using with live vaccines.


Adverse Effects:
Upper respiratory tract infection, herpes zoster, herpes simplex, bronchitis, nausea, cough, fever, acne, headache, allergy, folliculitis, nausea, abdominal pain, increased blood creatine.


Dosage form: Purple tablets.


Expiry date: 24 months from the date of manufacture.


Packaging: 15 mg/Tablet;28 Tablets/box.


Storage:
• Protected from light, sealed in original packaging, and stored at 20℃- 25℃.
• Keep out of reach of children.


DISCLAIMER

The information on this website about our medications is intended for general educational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay seeking care because of something you have read on this website.

For your safety:

Do not self-diagnose or treat any medical condition based solely on the information on this website. If you have any questions or concerns about a medication, please talk to your doctor or pharmacist.